Abstract:The cell division cycle 25 phosphatase B (Cdc25B) is involved in carcinogenic transformation and is a potential drug target for anticancer therapy. In order to screen Cdc25B inhibitors, 1,3-selenazole was selected as the core block, and 1,2,4-triazole Schiff base was bridged into 2-(1,2.4-triazol-3-yl)thio-N-(4-phenyl-1,3-selenazolyl-2-ypacetamide (TATS) by the amide thioether bond. The molecular docking simulation of TATS1 with Cdc25B was first performed to identify the rationality of the core function of 1,3-selenazole. The results show that 1,3-selenazole can be tightly embedded in the Cdc25B structure and perform N-H center dot center dot center dot PI non-bond weak interaction with the important catalytic site Arg492, which indicates that 1,3-selenazole plays a central role . The amide carbonyl oxygen atom forms a hydrogen bond with Arg492 and Arg488, indicating that the introduction of the amide thioether bond is reasonable. Based on the theoretical docking study, thirteen new target compounds TATS1 similar to TATS13 were designed and synthesized through modification in two regions of 1,2,4-triazole Schiff base. The inhibition against Cdc25B of target molecules and important intermediates was tested respectively. As a result, the inhibitory activities of the intermediates are not good, 12 target compounds have better biological activity than the positive reference substance Na 3 VO 4 , the modifications of two regions of 1,2,4-triazole also have a significant effect, which suggests that these compounds are expected to be a potential inhibitor of Cdc25B.

Synthesis and Cell Division Cycle 25b Phosphatase and Protein Tyrosine Phosphatase 1b Inhibitory Activity Evaluation of Novel 3,6-Disubstituted Triazolothiadiazole Derivatives

Synthesis and Cell Division Cycle 25B Phosphatase/Protein Tyrosine Phosphatase 1B Inhibitory Activity Evaluation of Novel Acylthiourea Derivatives

Synthesis and Cdc25B Inhibition Activity of Novel Imidazo[2,1-b][1,3,4]thiadiazole Derivatives

Synthesis, Characterization and Biological Activities of 3,5,6-Trisubstituted-1,2,4-triazine Derivatives

Synthesis and biological evaluation of novel thiadiazole amides as potent Cdc25B and PTP1B inhibitors.

Synthesis and PTP1B/TCPTP Inhibitory Activity Evaluation of Novel 2,5-Disubstituted-1,3,4-thiadiazolamide Derivatives Containing Carbazole/Benzimidazole Moity

Synthesis and Biological Activities of Novel 2,5-Disubstituted-1,3,4-thiadiazole Derivatives

Synthesis and Biological Evaluation of N-acylhydrazone Derivatives Containing Benzimidazole Moiety as Cdc25B and PTP1B Inhibitors

Synthesis and Cdc25B/PTP1B Inhibitory Activity Evaluation of Novel Acylhydrazone Derivatives Containing Carbazole Moity

Synthesis And Cdc25b/Ptp1b Inhibitory Activity Evaluation Of Novel Carbazole-Based Mono-/Bis-Thiocarbohydrazone Derivatives

Synthesis and antitumor activity evaluation of the derivatives of 1,2,4 - triazole -5 - thione bis - schiff base

Synthesis of Miltirone Analogues As Inhibitors of Cdc25 Phosphatases

Synthesis of Amide Thioether Bridged 1,3-Selenazole and 1,2,4-Triazole Derivatives and Their Inhibitory Activity Against Cell Division Cycle Phosphatase B (Cdc25b)

Synthesis and Antiproliferative Activity of Novel 1,3,4-Thiadiazole Derivatives

Design, synthesis, in silico and in vitro evaluation of thiophene derivatives: A potent tyrosine phosphatase 1B inhibitor and anticancer activity

Synthesis and Antiproliferative Activity of Thiadiazole Peptidomimetic Derivatives

Synthesis and Biological Evaluation of 1-(Benzofuran-3-yl)-4-(3,4,5-trimethoxyphenyl)-1h-1,2,3-triazole Derivatives As Tubulin Polymerization Inhibitors.

Identification of 1,3,4-Thiadiazolyl-Containing Thiazolidine-2,4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.

Synthesis, and biological evaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-a]pyridine analogues as new potent tubulin polymerization inhibitors

Synthesis and biological evaluation of novel 7-hydroxy-4-phenylchromen-2-one-linked to triazole moieties as potent cytotoxic agents.